Key result
The provided text contains only the editorial board listing and no clinical study data.
Why the study?
Are venous plasma ET-1 concentrations elevated in obese men with metabolic syndrome compared to controls?
Are venous plasma ET-1 concentrations elevated in obese men with metabolic syndrome compared to controls?
Elevated ET-1 levels in obese men with metabolic syndrome suggest it may contribute to the cardiovascular risk profile of this condition.
No data on ET-1 levels in metabolic syndrome; leaves open any contribution to cardiovascular risk.
We evaluated venous plasma ET-1 concentrations in 18 never-treated obese men (body mass index 31.0 +/- 0.5 kg/m2; age 45.4 +/- 4.3 years) showing the whole features of the above syndrome and 12 control men (age 44.1 +/- 3.6 years). Circulating ET-1 levels were significantly higher in patients than in controls (p < 0.05), and were directly correlated with fasting insulin levels (r = 0.564, p = 0.015) and erythrocyte Na+/Li+ counter-transport activity (r = 0.504, p = 0.033). In conclusion, venous plasma ET-1 levels are elevated in obese men manifesting the whole features of the metabolic syndrome. Due to the biological properties of ET-1, our findings suggest the peptide as a further component of the cluster of cardiovascular risk factors which characterizes this syndrome.
No takes yet. Share an insight, caveat, or question.
Ferri et al. (2009) studied obesity with metabolic syndrome. The provided text contains only the editorial board listing and no clinical study data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: